Work

551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.1742

Authors: J.H. Strickler, A. Cercek, K. Ng, S. Siena, T. André, E. Van Cutsem, C. Wu, A.S. Paulson, J. Hubbard, A.L. Coveler, C. Fountzilas, A. Kardosh, P.M. Kasi, H.J. Lenz, K.K. Ciombor, M.E. Elez Fernandez, M. Stecher, P. Cronin, M. Bieda, T. Bekaii-Saab

Institutions: Duke University, Duke Cancer Institute, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University of Milan, Hôpital Saint-Antoine, Universitair Ziekenhuis Leuven, Mayo Clinic Comprehensive Cancer Center (Arizona), Mayo Clinic, Fred Hutch Cancer Center, Roswell Park Comprehensive Cancer Center, Oregon Health & Science University, Weill Cornell Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, Vanderbilt University Medical Center, Vall d'Hebron Hospital Universitari, Seagen (United States), Mayo Clinic Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Seagen, Merck Sharp and Dohme

OpenAlex ID: W4387812013

FWCI: 0.235

Cites:

Cited by: 2

Related to: 10